BioTech
All initial communications will be channeled through Flusso Capital to maintain a streamlined and effective investment process for all stakeholders.
Thank you for being a valued partner in our network.
BT945680
Transformative approach to diagnostics, using AI-powered yeast-based technology to deliver rapid, cost-effective testing for critical health areas like metabolic disorders, chronic pain, and toxicology.
Positioned to address a high-demand, multi-billion dollar market, their innovative platform offers real-time, scalable diagnostics, reducing costs and regulatory challenges for healthcare providers. With an MVP already in place and partnerships underway, this is a compelling investment opportunity in a cutting-edge technology poised to redefine diagnostics and advance patient care.
BT275916
AI-driven drug development platform fighting against chronic diseases and aging. By targeting cellular aging, their therapies offer safer, more effective treatments for conditions like chronic kidney disease (CKD).
With successful preclinical results, proprietary technology, and partnerships with top institutions, the company is well-positioned in the $95B CKD market. Currently raising $3M to advance clinical trials, this is a prime opportunity for investors seeking high returns, with a potential exit via acquisition or IPO in 5-7 years.
BT102161
Pioneering the future of genetic data by giving individuals complete control and ownership of their DNA while enabling them to contribute directly to scientific research. By combining secure blockchain technology and AI-driven insights, they provide high-quality, customizable genomic data to researchers, addressing the critical demand for precision in genetic research.
With strong early traction, including pre-orders and significant interest from the research community, this is a groundbreaking opportunity to invest in the rapidly growing $140B genomic data industry.
BT424900
Combining advanced genetics and AI to create personalized anti-aging solutions. By targeting the root causes of skin aging—genetic and epigenetic factors—rather than just the symptoms, they offer innovative products like a personalized skin age testing kit and a unique anti-aging cream. With a rapidly growing global skincare market and a strong focus on scientific research, they are positioned to capture significant market share and expand into broader anti-aging treatments.
Backed by a team of experts and strategic partnerships, the company is set to redefine personalized skincare and lead the next wave of innovation in the beauty industry.
BT395845
Non-invasive, AI-driven urine test that accurately identifies urologic cancers like prostate, kidney, and bladder, addressing a $10B market.
Offering a cost-effective and scalable solution, their test provides an early-stage diagnosis at a fraction of the cost of traditional methods. With partnerships at top institutions and over 1,000 samples validated, they are poised for rapid growth.
Raising $3M to expand their cancer test portfolio, this is a unique investment opportunity in the booming cancer diagnostics space.